These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 29112242)
1. A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis. Ruutu T; Nihtinen A; Niittyvuopio R; Juvonen E; Volin L Cancer; 2018 Feb; 124(4):727-733. PubMed ID: 29112242 [TBL] [Abstract][Full Text] [Related]
2. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Ruutu T; Volin L; Parkkali T; Juvonen E; Elonen E Blood; 2000 Oct; 96(7):2391-8. PubMed ID: 11001889 [TBL] [Abstract][Full Text] [Related]
3. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768 [TBL] [Abstract][Full Text] [Related]
4. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Deeg HJ; Lin D; Leisenring W; Boeckh M; Anasetti C; Appelbaum FR; Chauncey TR; Doney K; Flowers M; Martin P; Nash R; Schoch G; Sullivan KM; Witherspoon RP; Storb R Blood; 1997 May; 89(10):3880-7. PubMed ID: 9160697 [TBL] [Abstract][Full Text] [Related]
5. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R; Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417 [TBL] [Abstract][Full Text] [Related]
6. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis. Kalhs P; Brugger S; Schwarzinger I; Greinix HT; Keil F; Kyrle PA; Knöbl P; Schneider B; Höcker P; Linkesch W Transplantation; 1995 Nov; 60(9):949-57. PubMed ID: 7491699 [TBL] [Abstract][Full Text] [Related]
7. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799 [TBL] [Abstract][Full Text] [Related]
8. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone. Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565 [TBL] [Abstract][Full Text] [Related]
9. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation. Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164 [TBL] [Abstract][Full Text] [Related]
10. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. Ross M; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM; Smith EP; Snyder DS; Stein AS; Wong RM; Forman SJ; Blume KG; Chao NJ Biol Blood Marrow Transplant; 1999; 5(5):285-91. PubMed ID: 10534058 [TBL] [Abstract][Full Text] [Related]
11. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757 [TBL] [Abstract][Full Text] [Related]
12. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Locatelli F; Bruno B; Zecca M; Van-Lint MT; McCann S; Arcese W; Dallorso S; Di Bartolomeo P; Fagioli F; Locasciulli A; Lawler M; Bacigalupo A Blood; 2000 Sep; 96(5):1690-7. PubMed ID: 10961865 [TBL] [Abstract][Full Text] [Related]
13. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants. Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935 [TBL] [Abstract][Full Text] [Related]
14. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease. Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553 [TBL] [Abstract][Full Text] [Related]
15. Low-dose cyclosporin A with short-term methotrexate for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation from human leukocyte antigen-identical siblings: a prospective phase II study in Japanese patients. Kohno A; Morishita Y; Iida H; Sakamaki H; Yokozawa T; Kitaori K; Ozeki K; Matsuo K; Sao H Int J Hematol; 2006 Jul; 84(1):83-9. PubMed ID: 16867909 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454 [TBL] [Abstract][Full Text] [Related]
17. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT. Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866 [TBL] [Abstract][Full Text] [Related]
18. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A; Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791 [TBL] [Abstract][Full Text] [Related]
19. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. Uberti JP; Silver SM; Adams PT; Jacobson P; Scalzo A; Ratanatharathorn V Bone Marrow Transplant; 1997 Jun; 19(12):1233-8. PubMed ID: 9208118 [TBL] [Abstract][Full Text] [Related]
20. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Schwinghammer TL; Bloom EJ Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]